HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Neuromyelitis Optica (Devic's Disease)

Subscribe to New Research on Neuromyelitis Optica

A syndrome characterized by acute OPTIC NEURITIS in combination with acute MYELITIS, TRANSVERSE. Demyelinating and/or necrotizing lesions form in one or both optic nerves and in the spinal cord. The onset of optic neuritis and myelitis may be simultaneous or separated by several months. (J Neurol Neurosurg Psychiatry 1996 Apr;60(4):382-387)

Also Known As:

Devic's Disease; Devic Syndrome; Devic's Syndrome; Devic Neuromyelitis Optica; Devic's Neuromyelitis Opticas; Devic's Syndromes; Devics Disease; Devics Neuromyelitis Optica; Devics Syndrome; Disease, Devic; Disease, Devic's; Neuromyelitis Optica, Devic's; Neuromyelitis Opticas, Devic's; Optica, Devic's Neuromyelitis; Opticas, Devic's Neuromyelitis; Syndrome, Devic; Syndrome, Devic's; Syndromes, Devic's; Devic Disease; Devic's Neuromyelitis Optica

Networked: 830 relevant articles (41 outcomes, 51 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Multiple Sclerosis
2.	Myasthenia Gravis
3.	Optic Neuritis (Retrobulbar Neuritis)
4.	Optic Nerve Diseases (Optic Neuropathy)
5.	Transverse Myelitis (Necrotizing Myelitis)

Experts

1.	Fujihara, Kazuo: 36 articles (01/2016 - 12/2004)
2.	Takahashi, Toshiyuki: 34 articles (10/2015 - 05/2007)
3.	Verkman, A S: 33 articles (11/2014 - 01/2009)
4.	Pittock, Sean J: 28 articles (09/2015 - 12/2004)
5.	Weinshenker, Brian G: 27 articles (07/2015 - 12/2004)
6.	Misu, Tatsuro: 26 articles (01/2016 - 05/2007)
7.	Bennett, Jeffrey L: 26 articles (08/2015 - 11/2009)
8.	Vincent, Angela: 25 articles (08/2015 - 04/2007)
9.	Wingerchuk, Dean M: 25 articles (07/2015 - 12/2004)
10.	Lucchinetti, Claudia F: 23 articles (01/2015 - 12/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neuromyelitis Optica:

1.	rituximab (Mabthera)FDA Link 03/01/2013 - "The effective treatment of neuromyelitis optica (NMO) with rituximab has suggested an important role for B cells in NMO pathogenesis. " 09/01/2015 - "Here we report four patients with severe relapsing neuromyelitis optica who were stabilized on rituximab and, after discontinuing treatment, continued to experience prolonged remission of their disease. " 03/01/2015 - "Rituximab, a chimeric monoclonal anti-CD20 antibody, has been proposed to be effective for neuromyelitis optica spectrum disorder (NMOSD). " 11/01/2013 - "Rituximab is widely used for the treatment of neuromyelitis optica, even though it has not received FDA approval for this condition anywhere in the world. " 12/01/2015 - "Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder."
2.	AntibodiesIBA 01/01/2010 - "Finally, there is growing evidence that treatments, which specifically target B cells and/or antibodies, are effective in MS and its variants neuromyelitis optica (NMO). " 12/01/2011 - "The detection of antibodies against aquaporin-4 (AQP4) has improved the diagnosis of neuromyelitis optica (NMO). " 12/01/2011 - "A cohort of 164 patients with MG. In 24 patients with MG, signs of CNS involvement were detected; 15 of these patients had at least 1 additional paraclinical indication of neuromyelitis optica-like disease (presence of antibodies against AQP4, pathological visual evoked potentials, or white matter lesions detected on brain and/or spinal magnetic resonance imaging scans) and fulfilled the inclusion and exclusion criteria for our study. " 12/10/2009 - "The current study presents a western blot assay showing good sensitivity (81%) and specificity (97%) for detecting serum antibodies to Aquaporin-4 (AQP4) in patients with Neuromyelitis Optica (NMO). " 12/01/2015 - "Antibodies to aquaporin-1 are not present in neuromyelitis optica."
3.	Immunoglobulin G (IgG)IBA 09/01/2008 - "Serial titers of neuromyelitis optica-immunoglobulin G normalized during remission." 01/01/2013 - "ANA test returned positive in 40%, oligoclonal banding (OCB) was identified in 31.3%, and Serum neuromyelitis optica (NMO)-IgG studies were abnormal in 25% of the patients. " 01/01/2010 - "In this study we aimed to describe the clinical NMO-IgG immunological status and neuroimaging characteristics of recurrent neuromyelitis optica in a series Brazilian patients. " 11/15/2009 - "Population-based epidemiological and genetic studies, with case ascertainment aided by the high specificity of NMO-IgG and consistent disease definitions, are needed to better define and understand gender effects in neuromyelitis optica." 10/30/2009 - "Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study."
4.	Retinaldehyde (Retinal)IBA 01/14/2014 - "In vivo identification of morphologic retinal abnormalities in neuromyelitis optica." 04/09/2013 - "To assess eyes with neuromyelitis optica (NMO) for morphologic retinal abnormalities utilizing high-definition optical coherence tomography (OCT) imaging. " 04/09/2013 - "In vivo identification of morphologic retinal abnormalities in neuromyelitis optica." 03/01/2010 - "To report changes in retinal nerve fiber layer (RNFL) thickness in a patient with neuromyelitis optica (NMO). " 03/01/2010 - "Retinal peripapillary nerve fiber layer thickness in a 13-year-old boy with neuromyelitis optica."
5.	natalizumab (Tysabri)FDA Link 01/01/2014 - "An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab." 01/01/2014 - "Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report." 07/01/2013 - "Natalizumab and the development of extensive brain lesions in neuromyelitis optica." 09/04/2012 - "Does natalizumab therapy worsen neuromyelitis optica?" 02/01/2012 - "Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy."
6.	Interferon-betaIBA 01/01/2014 - "Interferon-beta (IFN-β) treatment may not be effective in neuromyelitis optica (NMO). " 10/01/2012 - "Recent case reports and series have shown that patients with neuromyelitis optica (NMO) experience clinical deterioration under interferon beta (IFN-β) treatment. " 10/01/2012 - "Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?" 08/01/2012 - "Successful treatment of a woman with relapsing neuromyelitis optica by interferon beta." 09/01/2013 - "Reports have suggested that interferon beta which is beneficial for multiple sclerosis, exacerbates neuromyelitis optica. "
7.	Adrenal Cortex Hormones (Corticosteroids)IBA 09/01/2007 - "Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis." 11/01/2010 - "There are no specific treatments for patients with acute, severe neurological deficits caused by neuromyelitis optica (NMO) who fail to recover after treatment with high-dose corticosteroids. " 07/01/2012 - "To assess the contribution of plasma exchange (PE) in association (add-on) with pulsed intravenous corticosteroids in acute optic neuritis of neuromyelitis optica (NMO) and limited forms of NMO. " 02/01/2013 - "Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica." 07/01/2015 - "We investigated the efficacy of azathioprine (AZA) plus long-term low dose corticosteroids in Chinese patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) at the Center for Demyelinating Diseases, South China. "
8.	tocilizumab FDA Link 04/15/2014 - "To evaluate the safety and efficacy of a humanized anti-interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). " 04/15/2014 - "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study." 07/01/2013 - "Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab." 03/01/2013 - "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses." 10/01/2014 - "[Use of tocilizumab, an antibody against interleukin-6 receptor, for the treatment of neuromyelitis optica]."
9.	Methylprednisolone FDA LinkGeneric 03/01/2001 - "Intravenous methylprednisolone remains a viable treatment option to slightly increase the rate of recovery and provide a degree of short-term protection against the subsequent development of MS. Other inflammatory optic neuropathies include sarcoidosis, neuroretinitis, and Devic's disease with each possessing distinct clinical characteristics and treatment approaches." 12/01/2010 - "Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica." 01/01/2014 - "Impression of neuromyelitis optica spectrum disorder was made and patient was treated with methylprednisolone intravenously followed by tapering oral prednisone. "
10.	Complement System Proteins (Complement)IBA 02/01/2014 - "A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission." 09/15/2014 - "The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. " 11/01/2015 - "Role of membrane complement regulators in neuromyelitis optica." 05/01/2014 - "Evidence for classic complement activity in neuromyelitis optica." 06/01/2013 - "C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica."

Therapies and Procedures

1.	Plasmapheresis 01/01/2013 - "Although plasmapheresis is becoming standard practice as a rescue therapy for neuromyelitis optica (NMO), evidence for the therapeutic efficacy of plasmapheresis is limited, and the effect of plasmapheresis on anti-aquaporin-4 (AQP4) levels in patients with NMO has not been reported. " 01/01/2013 - "Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels." 11/01/2014 - "IVMP is also applied in the acute phase of neuromyelitis optica (NMO), with considerable benefit, although some patients are refractory to IVMP, and the early use of plasmapheresis should be considered in these patients. " 06/01/2014 - "A case of neuromyelitis optica spectrum disorder with early successful induction of double filtration plasmapheresis." 12/01/2009 - "Intermittent plasmapheresis prevents recurrence in neuromyelitis optica."
2.	Plasma Exchange 01/01/2015 - "[Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange]." 06/01/2014 - "Therapeutic plasma exchange in neuromyelitis optica: a case series." 11/01/2012 - "Plasma exchange for steroid unresponsive Devic's disease." 01/01/2012 - "Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica." 01/01/2012 - "Plasma exchange in severe attacks of neuromyelitis optica."
3.	Immunotherapy 01/01/2013 - "Immunotherapy of neuromyelitis optica." 10/01/2004 - "Further analysis will provide useful information to elucidate the pathogenesis and to develop immunotherapy for neuromyelitis optica and multiple sclerosis." 07/01/2015 - "Blood samples from10 anti-NMDAR encephalitis patients, 10 anti-NMDAR encephalitis patients whose physical conditions have improved after 3 months of immunotherapy, 20 virus (meningitis) encephalitis patients, 20 tuberculosis (meningitis) encephalitis patients, 10 purulent (meningitis) encephalitis patients, 20 cerebral cysticercosis patients, 20 ischemic stroke patients, 20 intracerebral hemorrhage patients, 15 neuromyelitis optica patients, 15 multiple sclerosis patients, 15 moyamoya disease patients, and 20 negative controls were collected for real-time quantitative PCR (qRT-PCR) analysis. " 04/01/2011 - "Twenty patients with highly relapsing NMO or neuromyelitis optica spectrum disorder who had at least 2 relapses during the year preceding the start of mitoxantrone treatment, despite other immunotherapies. "
4.	Molecular Targeted Therapy 11/01/2013 - "Developments in using monoclonal antibodies for molecular targeted therapy have demonstrated promising efficacy for various neuroimmunological diseases, including multiple sclerosis, neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and polymyositis. "
5.	Hematopoietic Stem Cell Transplantation 03/01/2014 - "Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica." 07/01/2011 - "Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica." 11/01/2010 - "Autologous peripheral hematopoietic stem cell transplantation (APHSCT) was performed to treat a patient with neuromyelitis optica. " 11/01/2010 - "A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation." 02/01/2015 - "Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party."